
Press Release
February 25, 2025
Kineticos Portfolio Company, Inceptor Bio, Announces First Patient Dosed in Clinical Trial and $21M Series A2 Financing
Kineticos Portfolio Company, Inceptor Bio, Announces First Patient Dosed in Clinical Trial of IB-T101 for Clear Cell Renal Cell Carcinoma…